Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 6 minute read Pharma Industry News Can Johnson & Johnson’s nipocalimab redefine autoimmune treatment by targeting Sjögren’s disease at its root? Nipocalimab showed major efficacy in Phase 2 Sjögren’s disease trial. Discover how Johnson & Johnson is advancing autoimmune therapies with its FcRn pipeline. bySrinathOctober 25, 2025